For most patients, primary treatment consisted of an anthracycline-containing chemotherapy regimen given preoperatively or postoperatively, with or without locoregional radiation therapy.
Trastuzumab was given every 3 weeks starting within 7 weeks of the completion of primary treatment.[128][Level of evidence A1] Patients were randomly assigned to one of three study arms:Observation (n = 1,693).1 year of trastuzumab (n = 1,694).2 years of trastuzumab (n = 1,694).Of the patients in the group comparing 1 year of trastuzumab versus observation, the median age was 49 years, about 33% had node-negative disease, and nearly 50% had hormone receptorâ€“negative disease.[129]The following results were observed for patients assigned to 1 year of trastuzumab versus patients assigned to observation:After a median follow-up of 11 years,[129] 1 year of trastuzumab improved DFS (10-year DFS rate, 72% vs.